Skip to main content
Premium Trial:

Request an Annual Quote

In Brief This Week: Roche, Cepheid; Anagnostics, Ramcon; InCellDx, Labco; Genome Designs; Prometheus

NEW YORK (GenomeWeb News) – Roche has initiated an arbitration hearing against Cepheid in response to Cepheid's decision to terminate its real-time PCR license with Roche, according to GenomeWeb Daily News sister publication PCR Insider. Cepheid had said in October that it was terminating the remainder of its PCR license with Roche "after determining that any patents remaining under the license are not pertinent to Cepheid's future business plans."

For more, see this week's issue of PCR Insider.

Anagnostics said this week that Ramcon A/S will exclusively sell the firm's hybcell drug screening tests and pharmacogenetics tests in Denmark, Sweden, Norway, Finland and Iceland.

IncellDx said this week that European clinical lab network Labco will now offer its HPV OncoTect assay throughout its entire network in Europe. Previously, Labco offered the test, which quantifies the overexpression of E6/E7 mRNA, on a limited basis.

Genome Designs, a Walnut Creek, Calif.-based sequencing informatics startup, said this week that it has received seed funding from undisclosed private investors and launched its operations. The firm didn't say how much in funding it received. It was founded by former employees of Argonne National Lab, NCBI, Integrated Genomics, and Ariadne. Genome Designs' CEO, Natalia Alexandrova, formerly served as marketing director at Ariadne.

Prometheus Laboratories has signed a research and collaboration agreement with an unnamed pharmaceutical firm to develop a pharmacogenomics assay for the partner's oncology pipeline. Prometheus will receive an upfront payment for development of the first assay, with additional payments for additional assays, as well as R&D support and testing fees.

In Brief This Week is a Friday column containing news items that our readers may have missed during the week.